Close

BioCryst Pharmaceuticals, Inc. (BCRX) Posts Wider Q2 Loss; Provides Update

August 8, 2013 8:41 AM EDT Send to a Friend
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q2 EPS of ($0.23), $0.09 worse than the analyst estimate of ($0.14). Revenue for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login